News
Novartis' radioligand therapy meets phase 3 prostate cancer ...
Novartis’ radioligand therapy Lu-PSMA-617 has met its target in prostate cancer, as its $2.1 billion acquisition of specialist pharma Endocyte looks to have been justified.
